Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An anti-enkephalin that decreases intestinal secretion.
Since the latest update, we have not found published data on its excretion in breast milk.
Its high percentage of protein binding makes it unlikely it will transfer to milk in significant quantities.
Possible side effects are not serious or frequent.
Its use is authorized in infants from 3 months of age (Pediamecum 2015)
Its indiscriminate use in treating gastroenteritis is not justified. Most cases of gastroenteritis do not require medication: good hydration is sufficient, even more so in the case of a breastfeeding mother.